HealthQuill Keytruda
Merck & Co., announced its trial drug along with a combination of the company’s Keytruda therapy failed to meet the main goal of overall survival in patients previously treated for a type of metastatic colorectal cancer. 
Drugs Health Pharma

Merck’s trial drug combination for colorectal cancer fails main goal

Merck & Co., announced its trial drug along with a combination of the company’s Keytruda therapy failed to meet the main goal of.

Read More
Merck & Co’s combination drug, Keytruda, which treats advanced lung cancer, has been approved by the US drug regulator, the Food and Drug Administration.
Drugs Health Pharma

Merck’s advanced lung cancer drug gets US drug regulator’s nod

Merck & Co’s combination drug, Keytruda, which treats advanced lung cancer, has been approved by the US drug regulator, the Food and Drug.

Read More
Swiss drugmaker, Roche, halted a lung cancer trial after it failed to meet the goal of progression-free survival compared to an existing treatment of Merck & Co.
Drugs Health Pharma

Roche ends small cell lung cancer trials as results show ‘reduced efficacy’

Swiss drugmaker, Roche, halted a lung cancer trial after it failed to meet the goal of progression-free survival compared to an existing treatment.

Read More
Moderna’s mRNA vaccine candidate in combination with Merck Co.’s, therapy, Keytruda, showed greater survival rates and efficacy in patients with skin cancer or melanoma.
Drugs Health Pharma

Moderna, Merck’s skin cancer vaccine shows rise in survival rates

Moderna’s mRNA vaccine candidate in combination with Merck Co.’s, therapy, Keytruda, showed greater survival rates and efficacy in patients with skin cancer or.

Read More
The Food and Drug Administration has approved Pfizer Inc.’s treatment for metastatic non-small cell lung cancer.
Drugs Medical Pharma

Merck discontinues trial for combo cancer drug for melanoma

HQ Team May 13, 2024: Merck has discontinued another cancer experimental immunotherapy treatment in patients with a severe form of melanoma due to.

Read More
Moderna Inc., a biotechnology company, and Merck announced that an experimental personalised cancer vaccine, based on the messenger RNA (mRNA) technology, has received Breakthrough Therapy Designation from the USFDA.
Drugs Health Pharma

Merck’s end-stage trials of endometrial cancer therapy fail to meet goals

HQ Team May 9, 2024: Merck announced that its Phase 3 trial evaluating Keytruda therapy in combination with chemotherapy, with or without radiotherapy,.

Read More
Moderna Inc., a biotechnology company, and Merck announced that an experimental personalised cancer vaccine, based on the messenger RNA (mRNA) technology, has received Breakthrough Therapy Designation from the USFDA.
Drugs Medical Pharma

Merck’s Keytruda receives FDA nod for cervical cancer treatment

HQ Team January 13, 2024: The U.S. Food and Drug Administration (FDA) has granted approval for the expanded use of Merck & Co’s.

Read More
Anixa Biosciences, Inc., announced that its partner Cleveland Clinic has begun enrolling subjects in a treatment arm to evaluate the combination of the company's breast cancer vaccine with Merck’s Keytruda (pembrolizumab) immunotherapy.
Drugs Health Pharma

Anixa to conduct breast cancer trials with Merck’s Keytruda therapy

HQ Team August 7, 2023: Anixa Biosciences, Inc., announced that its partner Cleveland Clinic has begun enrolling subjects in a treatment arm to.

Read More
Merck & Co., Inc., announced it has met one of the primary goals during a late-stage trial of its breast cancer therapy, Keytruda.
Drugs Health Pharma

Merck & Co meets breast cancer therapy goal in last-stage trials

HQ Team July 29, 2023: Merck & Co., Inc., announced it has met one of the primary goals during a late-stage trial of.

Read More
Merck Group’s investigational drug Keytruda, to treat gastric cancer, has failed to meet one of its two set goals, according to a NASDAQ filing.
Drugs Health Pharma

Merck’s Keytruda experimental gastric cancer drug flops in one of set goals

HQ Team June 20, 2023: Merck Group’s investigational drug Keytruda, to treat gastric cancer, has failed to meet one of its two set.

Read More